BiotechTube

HTL0018318 + Placebo

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dementia With Lewy Bodies

Conditions

Dementia With Lewy Bodies

Trial Timeline

Jul 1, 2019 → Jan 1, 2021

NCT ID
NCT03592862

About HTL0018318 + Placebo

HTL0018318 + Placebo is a phase 2 stage product being developed by Nxera Pharma for Dementia With Lewy Bodies. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03592862. Target conditions include Dementia With Lewy Bodies.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT03592862Phase 2Withdrawn
NCT03456349Phase 1Completed

Competing Products

20 competing products in Dementia With Lewy Bodies

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
69
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
ATH-1017 + PlaceboLeonaBioPhase 2
44
IGC AD1 + PlaceboIGC PharmaPhase 1
25
E2020 + PlaceboEisaiApproved
85
ARICEPTEisaiPhase 3
77
RasagilineEisaiPhase 2
52
Donepezil HydrochlorideEisaiPre-clinical
23
donepezil hclEisaiPhase 3
77
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placeboEisaiPhase 3
77
E2020 + E2020EisaiPhase 2
52
donepezil hydrochloride (Aricept)EisaiApproved
85
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
52
E2020 + E2020EisaiPhase 3
77
Irsenontrine + PlaceboEisaiPhase 2
52
E2020EisaiPhase 2
52
MecobalaminEisaiApproved
85
E2020 + PlaceboEisaiPhase 3
77
Donepezil HydrochlorideEisaiPhase 3
77

Other Products from Nxera Pharma

Daridorexant + PlaceboPhase 3
76
HTL0039732 Capsules + HTL0039732 Capsules and atezolizumab infusionPhase 1/2
40
HTL0009936 + HTL0009936 matching placeboPhase 1
32
HTL0018318Phase 1
32
HTL0018318 + Placebo oral capsulePhase 1
32